Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
China · Delayed Price · Currency is CNY 15.17
+0.07 (0.46%)
Sep 29, 2026, 11:30 AM CST
SHE:002932 Revenue
Wuhan Easy Diagnosis Biomedicine had revenue of 70.76M CNY in the quarter ending June 30, 2026, with 2.07% growth. This brings the company's revenue in the last twelve months to 267.22M, down -20.25% year-over-year. In the year 2025, Wuhan Easy Diagnosis Biomedicine had annual revenue of 265.08M, down -24.28%.
Revenue (ttm)
267.22M
Revenue Growth
-20.25%
P/S Ratio
11.87
Revenue / Employee
446.11K
Employees
599
Market Cap
3.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 265.08M | -84.98M | -24.28% |
| Dec 31, 2024 | 350.06M | -399.47M | -53.30% |
| Dec 31, 2023 | 749.54M | -9.78B | -92.88% |
| Jan 1, 2023 | 10.53B | 7.70B | 272.12% |
| Jan 1, 2022 | 2.83B | 1.87B | 195.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kehua Bio-Engineering Co.,Ltd | 1.69B |
| Chison Medical Technologies | 441.10M |
| Tellgen | 392.11M |
| Jiangsu Canopus Wisdom Medical Technology | 384.50M |
| Nanjing Medlander Medical Technology | 383.30M |
| Shanghai General Healthy Information and Technology | 371.61M |
| CareRay Digital Medical Technology | 319.79M |
| Beijing Leadman Biochemistry | 317.79M |